Please wait a minute...
文章检索
预防医学  2023, Vol. 35 Issue (1): 65-67    DOI: 10.19485/j.cnki.issn2096-5087.2023.01.015
  疾病控制 本期目录 | 过刊浏览 | 高级检索 |
浙江省1例AFP病例检出脊髓灰质炎疫苗高变异株病毒的流行病学调查
唐学雯1, 龚黎明2, 周洋1, 严睿1, 邓璇1, 朱瑶1, 何寒青1
1.浙江省疾病预防控制中心免疫规划所,浙江 杭州 310051;
2.浙江省疾病预防控制中心,浙江 杭州 310051
An epidemiological investigation on vaccine-hypervariable poliovirus in a case with acute flaccid paralysis in Zhejiang Province
TANG Xuewen1, GONG Liming2, ZHOU Yang1, YAN Rui1, DENG Xuan1, ZHU Yao1, HE Hanqing1
1. Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, China;
2. Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, China
全文: PDF(774 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 2021年6月,浙江省1例6月龄急性弛缓性麻痹(AFP)监测病例检出Ⅲ型脊髓灰质炎(脊灰)疫苗高变异株病毒(VHPV),分离培养的病毒与Sabin疫苗株相比在VP1区有6个核苷酸变异。病例有3剂次脊灰疫苗免疫史,发病时左上肢肌力Ⅱ级,临床诊断为肩蜂窝织炎(左侧),经治疗后恢复正常,神经系统检查无异常,痊愈出院。病例后续采集的标本中未再分离到VHPV,密切接触者中未检出VHPV,病例所在县区医疗机构主动搜索及社区人群搜索未发现类似病例。由于病例未出现VHPV所致脊灰的类似临床症状,经专家组讨论排除脊灰。本例VHPV发现及时,并采取有效措施,未造成病毒进一步传播,提示需继续保持AFP病例监测系统的敏感性,提高适龄儿童脊灰疫苗接种率,遏制脊灰病毒传播和流行。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
唐学雯
龚黎明
周洋
严睿
邓璇
朱瑶
何寒青
关键词 脊髓灰质炎脊髓灰质炎疫苗高变异株病毒急性弛缓性麻痹    
Abstract:Vaccine-hypervariable poliovirus type Ⅲ was detected in an acute flaccid paralysis infant at age of 6 months in Zhejiang Province in June, 2021, and the isolated and incubated virus had six nucleotide variations in the VP1 region as compared to the poliovirus Sabin vaccine strain. The infant had a history of three-dose poliovirus vaccination, and grade 2 muscle strength of the left upper limb upon onset. He was clinically diagnosed with cellulitis of the left shoulder, and recovered to normal following treatment. No abnormality was detected in the nervous system, and the infant was cured and discharged from hospital. No vaccine-hypervariable poliovirus was detected in subsequent infant' clinical samples or in close contacts, and no similar cases were identified during the active case detection by county/district medical institutions and among community populations. Since the infant did not present poliomyelitis-related clinical symptoms caused by vaccine-hypervariable poliovirus, poliomyelitis was excluded. The vaccine-hypervariable poliovirus was not spread because of timely identification and effective responses, suggesting the urgent need to maintain the sensitivity of the acute flaccid paralysis surveillance system and improve the coverage of poliovirus vaccination, so as to inhibit the transmission of poliovirus.
Key wordspoliomyelitis    vaccine-hypervariable poliovirus    acute flaccid paralysis
收稿日期: 2022-08-30      修回日期: 2022-10-24      出版日期: 2023-01-10
中图分类号:  R512.4  
基金资助:浙江省医药卫生科技计划项目(2021KY118)
通信作者: 何寒青,E-mail:hanqinghe@cdc.zj.cn   
作者简介: 唐学雯,硕士,副主任医师,主要从事免疫规划和疾病监测工作
引用本文:   
唐学雯, 龚黎明, 周洋, 严睿, 邓璇, 朱瑶, 何寒青. 浙江省1例AFP病例检出脊髓灰质炎疫苗高变异株病毒的流行病学调查[J]. 预防医学, 2023, 35(1): 65-67.
TANG Xuewen, GONG Liming, ZHOU Yang, YAN Rui, DENG Xuan, ZHU Yao, HE Hanqing. An epidemiological investigation on vaccine-hypervariable poliovirus in a case with acute flaccid paralysis in Zhejiang Province. Preventive Medicine, 2023, 35(1): 65-67.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2023.01.015      或      http://www.zjyfyxzz.com/CN/Y2023/V35/I1/65
[1] BIGOUETTE J P,WILKINSON A L,TALLIS G,et al.Progress toward polio eradication-worldwide,January 2019-June 2021[J].MMWR,2021,70(34):1129-1135.
[2] PATEL M,COCHI S.Addressing the challenges and opportunities of the polio endgame:lessons for the future[J/OL].J Infect Dis,2017[2022-10-24].https://doi.org/10.1093/infdis/jix117.
[3] SULTAN M A.Emerging challenges to realizing global polio eradication and their solutions[J].East Mediterr Health J,2022,28(7):515-520.
[4] 中华人民共和国国家卫生和计划生育委员会.脊髓灰质炎诊断:WS/T 294—2016[S].2016.
[5] KEW O,PALLANSCH M.Breaking the last chains of poliovirus transmission:progress and challenges in global polio eradication[J].Annu Rev Virol,2018,5(1):427-451.
[6] GARON J,SEIB K,ORENSTEIN W A,et al.Polio endgame:the global switch from tOPV to bOPV[J].Vaccines,2016,15(6):693-708.
[7] 祝双利,李晓嫘,朱晖,等.中国2015年脊髓灰质炎实验室网络的运转与评价[J].中国疫苗和免疫,2017,23(2):127-133.
[8] 唐学雯,周洋,邓璇,等.浙江省实施脊髓灰质炎疫苗免疫新策略的卫生经济学评价[J].预防医学,2017,29(12):1199-1202.
[9] 郭世成,胡志勇,刘莉红,等.江西省首例免疫缺陷疫苗衍生脊灰病毒病例的调查[J].现代预防医学,2016,43(5):922-924,930.
[10] YAO N,LIU Y,XU J W,et al.Detection of a highly divergent type 3 vaccine-derived poliovirus in a child with a severe primary
immunodeficiency disorder-Chongqing,China,2022[J].MMWR,2022,71(36):1148-1150.
[11] 龚震宇,龚训良.全球消除脊髓灰质炎进展[J].预防医学,2022,34(8):861-862.
[12] SHARIF S,ABBASI B H,KHURSHID A,et al.Evolution and circulation of type-2 vaccine-derived polioviruses in Nad Ali district of Southern Afghanistan during June2009-February 2011[J/OL].PLoS One,2014,9(2)[2022-10-24].https://doi.org/10.1371/journal.pone.0088442.
[13] HSU C H,HARVEY B,MOHAMED A,et al.Assessment of in-country capacity to maintain communicable disease surveillance and response services after polio eradication-Somalia[J].Vaccine,2020,38(5):1220-1224.
[14] 刘宇,方刚,杜飞,等.四川省Ⅱ型疫苗高变异脊髓灰质炎病毒/疫苗衍生脊髓灰质炎病毒循环事件的现场流行病学调查与分析[J].中国疫苗和免疫,2013,19(5):407-412.
[15] GOODMAN B.New York adult diagnosed with polio,first US case in nearly a decade[EB/OL].(2022-07-22)[2022-10-24].https://edition.cnn.com/2022/07/21/health/new-york-polio/index.html.
[1] 龚震宇, 龚训良. 全球消除脊髓灰质炎进展[J]. 预防医学, 2022, 34(8): 861-862.
[2] 王富良,刘仕俊,孙向珏,杜渐. 一起脊髓灰质炎减毒活疫苗接种偶合死亡案例分析[J]. 预防医学, 2018, 30(9): 943-945.
[3] 孙烨祥,林鸿波,李珊燕. 首剂IPV纳入免疫规划前儿童脊髓灰质炎疫苗接种情况分析[J]. 预防医学, 2017, 29(4): 368-371.
[4] 唐学雯,周洋,邓璇,严睿,谢淑云,何寒青. 浙江省实施脊髓灰质炎疫苗免疫新策略的卫生经济学评价[J]. 预防医学, 2017, 29(12): 1199-1202.
[5] 李倩, 胡昱, 张兵, 陈雅萍. 7岁以下儿童接种1剂次或2剂次Salk-IPV免疫效果的Meta分析[J]. 预防医学, 2016, 28(9): 874-878,895.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed